Article
Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.
Molecular oncology - 1 Nov 2023
Reissig Timm M, Ladigan-Badura Swetlana, Steinberg Anja, Maghnouj Abdelouahid, Li Ting, Verdoodt Berlinda, Liffers Sven T, Pohl Michael, Wolters Heiner, Teschendorf Christian, Viebahn Richard, Admard Jakob, Casadei Nicolas, Tannapfel Andrea, Schmiegel Wolff, Hahn Stephan A, Vangala Deepak B
Abstract excerpt
Although approximately half of all metastatic colorectal cancers (mCRCs) harbour mutations in KRAS or NRAS, hardly any progress has been made regarding targeted treatment for this group over the last few years. Here, we investigated the efficacy of vertical inhibition of the RAS-pathway by targeting epidermal growth factor receptor (EGFR) and mitogen-activated protein kinase kinase (MEK) in patient-derived...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.